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Abstract
Background—Despite chemical similarities, ADHD stimulants and methamphetamine have
distinct use patterns in the community. This study compared the characteristics of nonmedical
ADHD stimulants users and methamphetamine users in a household sample.
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Methods—In data from the 2009–2011 National Survey on Drug Use and Health, adult and
adolescent stimulant users were categorized into three mutually exclusive subgroups: nonmedical
ADHD stimulant users only (STM users), methamphetamine users (METH users), and both
nonmedical ADHD stimulant and methamphetamine users (STM/METH users). Multivariate
logistic regression analyses identified the substance comorbidity, mental health, and deviant
behavior characteristics associated with these three groups.
Results—Compared to adolescent STM users, STM/METH users were more likely to be female,
younger and uninsured while METH users were more likely to be younger, in a minority group
and from a higher-income family. Compared to adult STM users, METH and STM/METH users
were more likely to be male, older, uninsured, no longer married, and to be from rural areas.
Adolescent METH users were more likely than STM users to report illegal drug use while adult
METH users were less likely to report prescription drug use than their STM user counterparts.
Overall, adult and adolescent STM/METH users were more likely to report substance use, mental
health problems and deviant behaviors compared to STM users.
Conclusion—The characteristics of STM users differ from METH and STM/METH users, and
their associations with substance use and psychiatric comorbidities differ by age. Findings have
implications for understanding the risks for stimulant use in different age subgroups.
Keywords
Prescription stimulants; Substance abuse; Methamphetamine use; Mental health; Deviant
behaviors
1. Introduction
The past two decades have witnessed increased public concerns and research regarding
nonmedical use of prescription stimulants (Einhorn et al., 2012), particularly those
commonly prescribed for attention-deficit hyperactivity disorder (ADHD) (McCabe et al.,
2005, McCabe & Teter, 2007, McCabe et al., 2004, Safer et al., 1996, Teter et al., 2005,
Teter et al., 2006). Previous studies provide strong evidence that nonmedical use of
prescription stimulants is a growing problem especially among youth (Arria et al., 2008,
Johnston, 2003, McCabe et al., 2005, SAMHSA, 2009a, Teter et al., 2006, White et al.,
2006), and is associated with other substance use, mental health comorbidities, criminal
involvement, and cardiovascular conditions (NIDA, 2009).
Studies based on Monitoring the Future (MTF) and the National Survey on Drug Use and
Health (NSDUH) both showed that college students were twice more likely to report
nonmedical use of prescription stimulants than their counterparts not attending college
(Johnston, 2003, SAMHSA, 2009a). There are also reports that adolescents increasingly use
prescription stimulants nonmedically. In a web survey of a secondary school, 17.5% of
students reported both medical and nonmedical use of prescription stimulants, and 3.3%
reported nonmedical use only (McCabe & Teter, 2007). Another study of middle and high
schools showed prescription stimulants were used by 4.5% of students, with 23.3% reporting
being approached to sell, give, or trade these drugs (McCabe et al., 2004). The high
prevalence of nonmedical use among students could be explained by the use of these drugs
for cognitive enhancement. In past research, the most commonly reported motives for
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nonmedical prescription stimulants use in this age group were to help with concentration or
to study, followed by recreational use (Teter, et al., 2005; Teter, et al., 2006).
Methamphetamine (“speed,” “ice,” “crystal,” “crank,” or “glass”) is a highly addictive
stimulant which is similar in structure to amphetamine (DEA, 2013, Wu et al., 2007).
Although methamphetamine can be legitimately prescribed for treatment of ADHD,
narcolepsy and obesity, the medical use of this substance is extremely limited (NIDA,
2009). Most of methamphetamine use is illegal and has been linked to other substance use
disorders (DEA, 2013, Furr et al., 2000), high-risk sexual behaviors (Frosch et al., 1996),
HIV and HCV infections (Frosch et al., 1996, Gonzales et al., 2006), psychiatric and
behavior problems (Brecht et al., 2004, Gruenewald et al., 2010, Zweben et al., 2004), and
serious physical conditions (Darke et al., 2008, Kaye et al., 2008, Yu et al., 2003). In a
recent survey, about 11.9 million Americans aged 12 and older reported lifetime use of
methamphetamine (SAMHSA, 2012). Methamphetamine was reported as the primary
substance of abuse in 8% of all substance use treatment admissions, and accounted for 99%
of non-cocaine stimulant admissions (SAMHSA, 2009b).
ADHD stimulants and methamphetamine share several similarities. First, these drugs are
classified as schedule II based on the Controlled Substances Act (CSA), indicating their high
abuse potential (DEA, 2003). Second, nonmedical use of these drugs occurs mostly in young
individuals who are more likely to engage in other substance use or deviant behaviors
(Brecht et al., 2004, McCabe et al., 2005). Finally, ADHD stimulants and methamphetamine
are central nervous system stimulants with similar physiological effects such as activating
catecholamine system and adverse cardiovascular effects (Findling et al., 2001, Newton et
al., 2005). Despite these similarities, ADHD stimulants are distinct from methamphetamine
in that they are legitimately prescribed drugs, while the source of methamphetamine is
mainly illegal. More than 70% of nonmedical ADHD stimulant users reported their source
to be a friend who had legitimately obtained a prescription (Garnier-Dykstra et al., 2012). In
contrast, illegal production in clandestine laboratories using diverted pseudoephedrine
products and Mexican drug trafficking organizations contributed greatly to its widespread
availability (Cody, 2002, DEA, 2013).
Previous studies examining these two types of stimulants focused on young adults only and
were conducted prior to 2003 (Herman-Stahl et al., 2006, 2007, Wu et al., 2007).
Methamphetamine use decreased in the mid-2000s and then increased again around 2009–
2010, suggesting the need to conduct analyses using more contemporary data (Maxwell &
Brecht, 2011). Our study builds on earlier studies and further fills the information gap by
comparing nonmedical ADHD stimulant users to methamphetamine users on a broad range
of characteristics including socio-demographic, mental health and deviant behavior profiles,
and other substance use comorbidities (Herman-Stahl et al., 2006, 2007, Wu et al., 2007).
More specifically, in this study we examined the prevalence and correlates of nonmedical
use of ADHD stimulant, methamphetamine use, and both nonmedical ADHD stimulant and
methamphetamine use among adults (aged 18 and above) and adolescents (aged 12–17)
using data from the 2009–2011 NSDUH. We hypothesized that (1) the three groups would
differ with regard to important socio-demographic characteristics such as gender and age;
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and (2) methamphetamine use alone and in conjunction with nonmedical ADHD stimulant
use would be more strongly associated with comorbid mental health conditions, deviant
behaviors and other substance use than nonmedical ADHD stimulant use.
2. Methods
2.1. Study sample and measures
The NSDUH is an annual cross-sectional survey sponsored by the Substance Abuse and
Mental Health Administration (SAMHSA) and is designed to provide estimates of the
prevalence of alcohol and drug use in the household population of the United States. The
survey employs a 50-state design with an independent multistage area probability sample for
each of the 50 states and the District of Columbia. We used data from the 2009 (n = 55,772),
2010 (n = 55,873) and 2011 (n = 58,397) NSDUH public-use data files; three consecutive
NSDUH years were combined in order to increase sample size. Response rate across the
three years ranged from 87% to 89% for household screening and from 74% to 76% for
completed interviews. Survey items were administered by computer-assisted personal
interviewing (CAPI) and audio computer-assisted self-interviewing (ACASI). Respondents
were offered a $30 incentive payment for participation in the survey. There is no overlap of
respondents between NSDUH 2009 to 2011. Detailed information about the sampling and
survey methodology of NSDUH is found elsewhere (SAMHSA, 2009, 2010, 2011).
2.1.1. Nonmedical ADHD stimulant and methamphetamine use—ADHD
stimulants, defined as stimulants with specific indication for ADHD treatment, included
Ritalin® or methylphenidate, Cylert®, Dexedrine®, Dextroamphetamine, Adderall®,
Concerta®, and Vyvanse®. The survey used separate questions to assess nonmedical use of
any ADHD stimulants in the lifetime. Ritalin® or methylphenidate use was assessed in a
single question (“Have you ever, even once, used Ritalin or Methylphenidate that was not
prescribed for you or that you took only for the experience or feeling it caused?”). A similar
question was asked regarding the nonmedical use of Adderall®. However, Cylert®,
Dexedrine®, dextroamphetamine, Concerta® and Vyvanse® were ascertained by asking
respondents to look at all the categories of stimulants shown on a pill card and to identify
which stimulants they had ever used nonmedically.
Lifetime methamphetamine use was ascertained by two questions in NSDUH. First, the
respondents were asked: “Have you ever, even once, used meth, Desoxyn, or Methedrine
that was not prescribed for you or that you took only for the experience or feeling it
caused?” Second, the respondents were asked: “Methamphetamine, also known as crank,
ice, crystal meth, speed, glass, and many other names, is a stimulant that usually comes in
crystal or powder forms. It can be smoked, “snorted,” swallowed or injected. Have you ever,
even once, used methamphetamine?” NSDUH added the latter question in the noncore
section of the survey in order to capture information from respondents who may have used
methamphetamine but did not recognize it as a prescription drug. Methamphetamine use was
defined by a positive response to either question.
Based upon responses to the above questions, we created three mutually exclusive groups of
respondents: (1) nonmedical users of ADHD stimulants excluding methamphetamine users
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(STM users); (2) methamphetamine users excluding nonmedical ADHD stimulants users
(METH users); and (3) participants who used both ADHD stimulants nonmedically and
methamphetamine (STM/METH users).
2.1.2. Socio-demographic measures—Socio-demographic variables included in the
analyses for adults were gender, age (18–25, 26–34, 35–49, and >50 years), race/ethnicity
(white, black, Hispanic, other), marital status (married or living as married, divorced/
separated/widowed, never married), employment status (partial or full employment,
unemployed, not in labor force), education (less than high school, high school, college and
above), annual household income (≤ $19,999, $20,000–$34,999, $ 35,000–$69,999, ≥
$70,000), health insurance status (no insurance, any insurance), and urbanicity
(metropolitan, suburban, rural). Socio-demographic variables for adolescents were gender,
age (12–13, 14–15, and 16–17 year), race/ethnicity, annual household income, insurance
status, and urbanicity.
2.1.3. Other substances use measures—Past-year marijuana, cocaine, heroin,
hallucinogen, ecstasy, tranquilizer, sedative, inhalant, alcohol, and prescription opioid use
were assessed by asking participants a series of questions worded as follows: “Have you
ever, even once, used [alcohol or drug name]?”).
2.1.4. Past-year mental health and deviant behavior variables—Past-year mental
health treatment use was ascertained by asking participants whether they received any
mental health treatment in the past 12 months, including inpatient, outpatient treatment or
counseling for emotional or behavioral problems. NSDUH explicitly asked the respondents
not to include treatment for alcohol or drug use.
Past-year major depressive episode (MDE) was ascertained using a structured interview
based on the Diagnostic and Statistical Manual of Mental Disorders–IV (DSM-IV) criteria
(American Psychiatric Association, 1994). The diagnostic assessment was modeled after the
Composite International Diagnostic Interview (CIDI) as implemented in the National Co-
morbidity Survey-Replication (NCS-R) study (Kessler et al., 2003). CIDI has been shown to
have an acceptable level of agreement with clinician-administered interviews (Andrews &
Peters, 1998, Wittchen, 1994).
Past-year anxiety disorder was ascertained by asking the respondents if they were told by “a
doctor or other medical professional” that they had an “anxiety disorder” in the past 12
months.
Past-year deviant behaviors were assessed by asking the respondents how many times in the
past 12 months they had been arrested and booked for breaking the law (not counting minor
traffic violations), had attacked someone with the intent to seriously hurt them, had sold
illegal drugs, and had stolen or tried to steal anything worth more than $50. These four
indicators of deviant behaviors were assessed for both adolescent and adult participants.
Consistent with past research, participants who reported any of the four behaviors were
categorized as having “deviant behavior” (0 for none of these behaviors and 1 for engaging
in these behaviors 1 time or more) (Martins et al., 2006; Martins et al., 2009).
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Analyses were conducted in two stages. First, we compared socio-demographic
characteristics of METH users, and STM/METH users, to STM users (the reference group
for all analyses). Next, we compared METH and STM/METH users to the STM users on
measures of past-year substance use, mental health profile (past-year MDE, anxiety
disorder, mental health service use), and deviant behaviors. These comparisons were
conducted separately for adults and adolescents (with the age cutoff of 18). Multivariate
logistic regression analyses were performed within age groups for adults and adolescents
adjusted for age, gender, race, income, insurance, urbanicity, and year. Analyses in adult
group were additionally adjusted for marital status, education, and employment status.
Data were weighted to reflect the complex design of the NSDUH sample and were analyzed
using Stata 13.0 software (StataCorp, 2013). We used Taylor series linearization method to
obtain proper standard error estimates.
3. Results
3.1. Socio-demographic profiles of adolescent and adult users (Tables 1 and 2)
The prevalence of METH and STM/METH use was higher in adults than in adolescents
while STM use had a similar prevalence in the two groups. Among adolescent respondents
aged 12–17, 2.6% (n=1,592) were categorized as STM users, 0.4% (n=197) as METH users
and 0.4% (n=229) as STM/METH users. Among the adult respondents aged 18 and above,
3.1% (n=7,267) were categorized as STM users, 4.5% (n=4,640) as METH users and 1.5%
(n=2,282) as STM/METH users.
Compared to STM users, adolescent STM/METH users (Table 1) were more likely to be
female, Hispanic, and to reside in a suburban than metropolitan setting, but less likely to be
older (aged 16–17 vs. aged 12–13), and insured. Adolescent METH users (vs. STM users)
were more likely to be in a minority group (vs. white) and from a higher-income family
(household income ≥ $75,000 vs. < $20,000) but less likely to be older (aged 16–17 vs. aged
12–13).
For adults (Table 2), the age differences across the three groups were remarkably salient:
50.7% of the STM users were between age 18–25; 72.9% of METH users and 55.0% of
STM/METH users were older than 35 years. Compared to adult STM users, adult METH
and STM/METH users were more likely to be male, older, uninsured, no longer married (vs.
currently married or living as married), having education less than high school, from a
higher income family (vs. family income < $20,000), and from rural areas (vs. urban). Adult
METH users were more likely than adult STM users to be of Hispanic or other ethnic groups
(vs. non-Hispanic-whites), while no racial differences were found between STM/METH
users and STM users.
3.2. Past-year substance use, mental health and deviant behaviors in adolescents (Table 3)
Adolescent STM/METH users were significantly more likely than STM users to report all
types of past year substance use except for alcohol use. In contrast, adolescent METH users
were only more likely to report cocaine (aOR=2.15[1.14, 4.04]), ecstasy use (aOR=1.19
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[1.17, 3.10]) and inhalants (aOR=1.97 [1.15, 3.39]) compared to STM users. Adolescent
STM/METH users were also more likely than STM users to report mental health conditions
including anxiety disorder (aOR=3.42 [2.26, 5.16]), having received mental health treatment
(aOR=2.07 [1.41, 3.04]), and all types of deviant behaviors (arrested and booked: aOR=2.21
[1.46, 3.34]; sold illegal drugs: aOR=3.57 [2.22,5.73]; stole: aOR=2.46 [1.56, 3.87];
attacked someone: aOR=2.39 [1.61,3.55]). No differences were observed between METH
users and STM users regarding mental health and deviant behaviors.
3.3. Past-year substance use, mental health and deviant behaviors in adults (Table 4)
Adult METH users were less likely than STM users to report using prescription drugs
nonmedically in the past-year, including prescription opioids (aOR=0.64 [0.51, 0.80]),
tranquilizers (aOR=0.60 [0.44, 0.82]), and sedatives (aOR=0.35 [0.17, 0.72]). In contrast,
adult STM/METH users were more likely than STM users to report using all other
substances except for alcohol. There were no differences between METH users and STM
users with regard to mental health conditions, whereas STM/METH users were more likely
than STM users to report a past-year anxiety disorder (aOR=1.75 [1.21, 2.53]). Of note,
there was a trend for STM/METH users to be more likely to report all types of deviant
behaviors examined (arrested and booked: aOR=1.59 [1.24, 2.03]; sold illegal drugs:
aOR=2.33 [1.76,3.10]; attacked someone: aOR=1.38 [1.02,1.88]), except for stealing, while
METH users were more likely to report being booked or arrested (aOR=1.71 [1.29, 2.27])
and less likely to report stealing (aOR=0.61 [0.38, 0.99]) as compared to STM users.
4. Discussion
There were three main findings in this study. First, socio-demographic characteristics of the
three stimulant use groups differed, and the pattern of variations was different in the two age
subgroups. For instance, adolescent methamphetamine users were more likely to be female
while adult methamphetamine users were more likely to be male (compared to nonmedical
ADHD stimulant users). Second, adolescent stimulant users showed remarkably distinct
substance use comorbidities compared to adult stimulant users: adolescent METH users
were more likely to report illegal drug use as compared to adolescent STM users; whereas,
adult METH users were more likely to report prescription drug use compared to adult STM
users. Third, adult and adolescent STM/METH users in both age groups had a higher
prevalence of substance use, mental health conditions and deviant behaviors compared to
STM users.
The gender distribution of the three stimulant user groups also differed between adolescents
and adults. In adults, more than 60% of METH and STM/METH users were male; in
contrast, more than half of adolescent METH and STM/METH users were female. Past
research suggested that males and females were equally likely to use methamphetamine
(Durell et al., 2008, Kroutil et al., 2006, SAMHSA, 2005), while other studies have shown
that in the younger age group, females are more likely than males to use methamphetamine
(Herman-Stahl et al., 2006, 2007, Wu et al., 2007). In a previous study, females were five
times more likely than males to use methamphetamine for weight loss, which might explain
why female adolescents are more likely than their male counterparts to use
methamphetamine (Brecht, et al., 2004).
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The age differences between the three stimulant users groups in adults were striking. More
than half of the adult STM users were aged 18–25; whereas, the majority of adult METH
and STM/METH users were older than 35 years old. Our findings corroborate past research
on the age distribution of ADHD stimulants which are mainly used nonmedically by
adolescents and young adults (Herman-Stahl et al., 2006, 2007, McCabe et al., 2005,
SAMSHA, 2008, Teter et al., 2006). Previous NSDUH reports in early 2000s showed that
methamphetamine users were mostly aged 18–25 (Durell et al., 2008, SAMHSA, 2005). Our
study using the most recent NSDUH data points out that a large proportion of
methamphetamine users are in the 35 years old and older age group, suggesting the
possibility of a cohort effect – that is, previously young users who are now in their middle-
age continue using this drug as they age.
Consistent with many prior studies, this study showed nonmedical ADHD users were
proportionally more likely to be white (McCabe et al., 2007, McCabe et al., 2005, Teter et
al., 2006). Our study further revealed that METH users were significantly more likely than
STM users to be Hispanic in both the adolescent and adult groups. Since Hispanics now
comprise the largest and fastest growing minority group in the US (Ennis, 2011), the fact
that METH users (vs. STM users) were more likely to be Hispanics than whites highlights
the need for culturally-sensitive preventive strategies targeting Hispanics to diminish
methamphetamine use in this subpopulation.
The finding of significant comorbidity with other substances is consistent with past research
(Brecht et al., 2004, Durell et al., 2008, McCabe & Teter, 2007, NIDA, 2009, Teter et al.,
2006). One unique finding is that adolescent METH users had different drug use profiles
than adult METH users. Adolescent METH users were more likely to have used other
stimulants (cocaine and ecstasy) compared to adolescent STM users. In contrast, adult
METH users were less likely to report using other prescription drugs nonmedically
compared to adult STM users. As the most common source of nonmedically used
prescription drugs is from friends or relatives who obtained these medications from medical
provider (Garnier-Dykstra et al., 2012, Schepis & Krishnan-Sarin, 2009), it is likely that
adult STM users obtained ADHD stimulants as well as tranquilizers or sedatives from the
same source. Further studies of the users’ motivations and sources are needed to better
understand these distinct substance use profiles in adults and adolescents.
Not surprisingly, respondents in the STM/METH group were more likely to use multiple
drugs and to have mental health problems and deviant behaviors compared to STM users;
this phenomenon held for adults and adolescents. It indicates that STM/METH group has a
higher prevalence of comorbidities and problematic behaviors that require greater clinical
attention. Comorbid substance use and psychiatric disorders confer an additional risk for
poorer prognosis for individuals with substance use problems (Hasin et al., 2007; Hedden et
al., 2009; Strain, 2002). One study pointed out more substance comorbidities indicated not
only higher service use but also higher perceived unmet need for treatment (Chen et al.,
2013), suggesting that more clinical resources should be allocated to STM/METH group.
This study has several strengths, including its large sample size and generalizability to the
US household population. However, our findings should be interpreted in light of several
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limitations, mainly inherent to NSDUH design. First, the cross-sectional survey data limits
assessment of temporal relationship. Second, the ascertained methamphetamine users might
include medically prescribed Desoxyn or Methedrine users although they were not
commonly prescribed (DEA, 2013). Third, among the mental health measures selected in
this study, only major depressive episode was assessed via a screening instrument, while
ascertainment of anxiety disorder was subject to health care utilization. Fourth, we were not
able to explore whether individuals who used ADHD stimulants nonmedically had used
these drugs under a provider’s supervision in the past, which has implications for prevention
strategy. Fifth, NSDUH does not include homeless and jailed individuals who may have a
higher prevalence of substance disorders or more severe disorders. Lastly, all the
information is based on self-report, which may be vulnerable to recall bias.
5. Conclusion
Different population groups are at risk for nonmedical ADHD stimulant use,
methamphetamine use or use of both types of drugs. Socio-demographics and psychiatric
characteristics, as well as substance comorbidities across the three groups differ in adults
and adolescents. Future studies are needed to better explain these differences, including
possible differences in the motives for drug use and the temporal relationship of drug use
and mental health problems. Given that STM/METH users have more severe psychiatric
comorbidities and behavior problems, more clinical and social resources should be allocated
to this subgroup.
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• Methamphetamine and nonmedical ADHD stimulant users have different
characteristics.
• Social and mental health profiles of users of different stimulants vary by age.
• Users of both stimulant group have poorer social and mental health outcomes.
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